Orphan Drug Adoption: The More Regulation, The Better

Clark Herman cites a recent survey conducted by a Merck executive that found that countries with stronger mechanisms for promoting orphan drug development do better at providing therapies to patients with rare diseases. Additionally, countries with more medical regulations, rather than a stronger free market, are better able to serve this population.
PharmExec.com